

NanoLuc[®] Binary Technology

A Structural Complementation Reporter Designed for Cellular Protein Analysis

Dr. Erik Bonke | Application Specialist | Promega GmbH


Welcome





Promega – The Bioluminescent Company

A Continuously Grown Expertise in Luciferase-based Technologies



- Reporter Gene Assays
- GloSensor™ (cAMP, Protease Assays)
- GloResponse™ (Signaling Pathways)
- Rapid Response™ (Signaling Pathways)
- Cell-Health Assays
- Bioassays (ADCC, PDL1)
- NanoBRET™ Target Engagement
- NanoBRET™ / NanoBiT® Protein:Protein Interaction
- HiBiT Protein Tagging System
- Lumit™ Immunoassays





NanoLuc[®] Luciferase

A Bright & Small Experimental Reporter



Wang *et al.* 2015

Oplophorus gracilirostris








NanoLuc[®] Luciferase

A Bright & Small Experimental Reporter

Bright, Brighter, NanoLuc[®]




Small, Smaller, NanoLuc[®]





Promega – The Bioluminescent Company

A Continuously Grown Expertise in Luciferase-based Technologies





- Reporter Gene Assays
 - GloSensor™ (cAMP, Protease Assays)
 - GloResponse™ (Signaling Pathways)
 - Rapid Response™ (Signaling Pathways)
 - Cell-Health Assays
 - Bioassays (ADCC, PDL1)
 - NanoBRET™ Target Engagement
 - NanoBRET™ / NanoBiT® Protein:Protein Interaction
 - HiBiT Protein Tagging System
 - Lumit™ Immunoassays
- ↓ ↓ ↓
NanoBiT® Technology Platform



NanoLuc[®] Binary Technology (NanoBiT[®])

A Structural Complementation Reporter Designed for Biomolecular Interaction Studies






NanoBiT[®] Protein:Protein Interaction System

Investigate Interaction Dynamics in Live Cells


Small tag size

minimal influence on fusion partner



Bright signal upon complementation

enables low expression levels



Low intrinsic affinity


reversible to allow investigation of PPI dynamics

increased signal specificity



NanoBiT[®] PPI Workflow

A Simple Transfection-based Experiment



Cloning & Transfection

+ Nluc Substrate/Treatment


Measure

- 1 Determine optimal LgBiT/SmBiT combinations that shows maximal fold signal increase *tool compound versus vehicle control or in comparison to HaloTag[®]-SmBiT negative control*
- 2 Check for signal specificity
expected response to tool compound or signal of SmBiT/LgBiT fusions 10 – 1,000-fold higher than LgBiT fusion co-expressed with HaloTag[®]-SmBiT (general guideline)



Competition with Untagged Protein


Check for Specificity in NanoBiT[®] PPI Assays



- Titrate the level of untagged fusion partner
- # of unproductive pairings \uparrow
- Specific interaction will show decrease in luminescence
- Nonspecific interaction will show no change in luminescence


Validation of NanoBiT[®] PPI

The Protein Kinase A Model



Validation of NanoBiT[®] PPI

The Protein Kinase A Model



Isoproterenol (ISO)

ADRB agonist (cAMP ↑)

Propranolol (PRO)

ADRB antagonist (cAMP ↓)

Forskolin (FSK)

activator of adenylate cyclase (cAMP ↑)

Conclusions

- Endogenous biology is maintained with the NanoBiT[®] PPI System
- The NanoBiT[®] PPI System functions in a reversible manner



Ready-to-use NanoBiT[®] PPI Assays


- Pre-optimized *ready-to-use* protein:protein interaction pairs
- *Ready-to-use* stable cell lines
- BiBiT System: Generate your own stable cell line
- Available through **Elite Access (EA)**

| | | | |
|-----------------------------|-------------------------|-------------------------|-----------------------------|
| AR:AR (NR3C4/NR3C4) | EGFR(1-673):EGFR(1-673) | BRD4:Histone 3.3 | L3MBTL3:BCLAF1 |
| MYC:MAX | AR:SRC1 | EPOR(1-273):EPOR(1-273) | PDGFRA(1-549):PDGFRA(1-549) |
| FKBP:FRB | KRAS 2A G12D:CRAF | GR:GR (NR3C1:NR3C1) | PDGFRA(1-549):PDGFRB(1-553) |
| p53:MDM2 | PD-1:SHP1 | EGFR:GRB2 | PDGFRB(1-553):PDGFRB(1-553) |
| PRKACA:PRKAR2A | PD-L1:PD-L1 | HER1(1-668):HER2(1-675) | RELA:NFKBIA |
| BRAF:CRAF | PD-L2:PD-L2 | HER1(1-668):HER3(1-664) | |
| CRAF:CRAF | CX3CR1:ARRB2 | HER3(1-664):HER3(1-664) | |
| BRAF:BRAF | ADRB2:ARRB2 | KRAS (G12C):CRAF | |
| HER2(1-657):HER3(1-664) | AVPR2:ARRB2 | KRAS (G12C):CRAF | |
| VEGFR1(1-785):VEGFR1(1-785) | BCL2:BAK | KRAS:CRAF | |



NanoLuc[®] Binary Technology (NanoBiT[®])

A Structural Complementation Reporter Designed for Biomolecular Interaction Studies






Complementation facilitated through ...

(indirect) Ab:Ab “interaction”



Lumit[™] Immunoassays


Hwang *et al.* 2020, *Commun Biol.*



Lumit™ Immunoassays

The Powerful Alternative to Conventional Immunoassay Approaches


Traditional ELISA Workflow



- Traditional ELISA is a heterogenous multistep process involving several wash / incubation steps

Lumit™ Immunoassays

The Powerful Alternative to Conventional Immunoassay Approaches






- Traditional ELISA is a heterogenous multistep process involving several wash / incubation steps
- Based on NanoLuc® luciferase we developed *Lumit™ Immunoassays*
 - ✓ Easy and fast (30 – 120 min)
 - ✓ High Sensitivity (low number of cells)
 - ✓ Broad dynamic range (3 – 4 logs)
 - ✓ Flexible formats (96- or 384-well)
 - ✓ Homogenous and HTS compatible



Lumit™ Immunoassays

Different Formats for Maximum Flexibility


| Direct | Indirect | Competitive |
|--|---|---|
|  <p>1° Ab-LgBiT 1° Ab-SmBiT</p> <p>Analyte</p> |  <p>2° Ab-LgBiT 2° Ab-SmBiT</p> <p>1° Ab #1 1° Ab #2</p> <p>Analyte</p> |  <p>Analyte Labeled Tracer Labeled Antibody</p> |
| <ul style="list-style-type: none">• Requires labeling of 1°Abs• Validated for cytokines and peptide hormones• <i>Ready-to-use</i> assays for<ul style="list-style-type: none">✓ IL1-β, IFN-γ, IL-2, IL-6, IL-10, IL-4, TNF-α, VEGF, ...✓ Insulin and glucagon | <ul style="list-style-type: none">• Avoids labeling of 1°Abs• Generic pre-labeled 2°Abs (different species available)• Validated for intracellular PTMs, e.g. phosphorylation | <ul style="list-style-type: none">• Requires antibody and tracer labeling• Establish competitive antibody binding assays• <i>Ready-to-use</i> assays for hFcRn:Fc protein interactions<ul style="list-style-type: none">✓ Lumit™ FcRn Binding Immunoassay✓ hFcγ receptor assays (<i>under development</i>) |



Lumit™ Immunoassays


Different Formats for Maximum Flexibility

Direct




- Requires labeling of 1°Abs
- Validated for cytokines and peptide hormones
- *Ready-to-use* assays for
 - ✓ IL1-β, IFN-γ, IL-2, IL-6, IL-10, IL-4, TNF-α, VEGF, ...
 - ✓ Insulin and glucagon

Indirect



- Avoids labeling of 1°Abs
- Generic pre-labeled 2°Abs (different species available)
- Validated for intracellular PTMs, e.g. phosphorylation

Competitive




- Requires antibody and tracer labeling
- Establish competitive antibody binding assays
- *Ready-to-use* assays for hFcRn:Fc protein interactions
 - ✓ Lumit™ FcRn Binding Immunoassay
 - ✓ hFcγ receptor assays (*under development*)




Build-Your-Own Direct Lumit™ Immunoassay


Various Options for Your Convenience



😊 highest specificity and sensitivity



😊 only one mAb needed




😊 most inexpensive variant



Build-Your-Own Direct Lumit™ Immunoassay

Step 1: Labeling of Antibodies with the Lumit™ Immunoassay Labeling Kit





FACTS

- Easy and robust 2-day protocol
- Attachment is highly efficient (> 90%)
- Oriented BiT subunits for maximum activity



Build-Your-Own Direct Lumit™ Immunoassay

Step 1: Labeling of Antibodies with the Lumit™ Immunoassay Labeling Kit




FACTS

- Easy and robust 2-day protocol
- Attachment is highly efficient (> 90%)
- Oriented BiT subunits for maximum activity
- Removal of unbound HT-BiTs is not required




Build-Your-Own Direct LumitTM Immunoassay


Various Options for Your Convenience



😊 highest specificity and sensitivity



😊 only one mAb needed





😊 most inexpensive variant





Build-Your-Own Direct Lumit™ Immunoassay

Step 2: Identification of best antibody combination/concentration

Matrix experiment to determine maximal signal-to-background (S/B) ratio



Background






mAb-LgBiT
0.125 $\mu\text{g/ml}$
+
pAb-SmBiT
1 $\mu\text{g/ml}$



Build-Your-Own Direct Lumit™ Immunoassay

Various Options for Your Convenience



😊 highest specificity and sensitivity


😊 only one mAb needed

😊 most inexpensive variant




Build-Your-Own Direct Lumit™ Immunoassay

Step 3: Functional Test of Identified Antibody Combination



Lumit™ (human) IFN- γ Immunoassay



OBSERVATIONS


- Good sensitivity and broad dynamic range (≥ 3 logs)
- No need for sample dilution



Build-Your-Own Direct Lumit™ Immunoassay

Step 3: Functional Test of Identified Antibody Combination


BiTE-induced IFN- γ release from CD8⁺ T cells



BiTE: Bispecific T cell engager

scFv: single-chain variable fragment

Lumit™ (human) IFN- γ Immunoassay



OBSERVATIONS


- Good sensitivity and broad dynamic range (≥ 3 logs)
- No need for sample dilution
- Excellent cell-based performance (addition to cells)



Measure Protein:Protein Interactions

Lumit™ SARS-CoV-2 Spike RBD:hACE2 Immunoassay

Detection of neutralizing antibodies and other inhibitory molecules that block the interaction of SARS-CoV-2 and the human surface protein ACE2



Safe

- In contrast to plaque reduction neutralization test (PRNT) no need for high BSL environment

Fast

- Faster than PRNT and other ELISA-based surrogate virus neutralization tests (VNT): hours vs. days

Homogenous, in-solution assay format


- No immobilization, blocking, washing, and transfer steps
- Flexible formats (96- or 384-well)
- Amenable to HTS



Measure Protein:Protein Interactions

Lumit™ SARS-CoV-2 Spike RBD:hACE2 Immunoassay

Detection of neutralizing antibodies and other inhibitory molecules that block the interaction of SARS-CoV-2 and the human surface protein ACE2



Safe

- In contrast to plaque reduction neutralization test (PRNT) no need for high BSL environment

Fast

- Faster than PRNT and other ELISA-based surrogate virus neutralization tests (VNT): hours vs. days


Homogenous, in-solution assay format

- No immobilization, blocking, washing, and transfer steps
- Flexible formats (96- or 384-well)
- Amenable to HTS



Lumit™ SARS-CoV-2 Spike RBD:hACE2 Immunoassay



A Homogenous and Fast to Accomplish Workflow





Lumit™ SARS-CoV-2 Spike RBD:hACE2 Immunoassay

Soluble ACE2 & Neutralizing Antibodies



Lumit™ SARS-CoV-2 Spike RBD: hACE2 Immunoassay ...


- detects the competition effect of a soluble ACE2 protein on the RBD:ACE2 PPI
- detects neutralizing antibodies that inhibit the interaction
- can be used as a surrogate virus neutralization test (VNT) to analyze patient serum neutralizing antibody levels post SARS-CoV-2 infection and/or vaccination (data not shown)



Lumit™ Immunoassays


Different Formats for Maximum Flexibility

Direct




- Requires labeling of 1°Abs
- Validated for cytokines and peptide hormones
- *Ready-to-use* assays for
 - ✓ IL1-β, IFN-γ, IL-2, IL-6, IL-10, IL-4, TNF-α, VEGF, ...
 - ✓ Insulin and glucagon

Indirect



- Avoids labeling of 1°Abs
- Generic pre-labeled 2°Abs (different species available)
- Validated for intracellular PTMs, e.g. phosphorylation

Competitive




- Requires antibody and tracer labeling
- Establish competitive antibody binding assays
- *Ready-to-use* assay for hFcRn:Fc protein interactions, e.g. antibodies
 - ✓ Lumit™ FcRn Immunoassay



Lumit™ Immunoassay Cellular Systems

Study Cellular Signaling Events




Additionally available pre-labeled 2° Abs:

- anti-rabbit (LgBiT)
- anti-mouse (SmBiT)
- anti-goat (LgBiT)
- anti-goat (SmBiT)



Lumit™ Immunoassay Cellular Systems


Study Cellular Signaling Events






Lumit™ Immunoassay Cellular Systems

Study Cellular Signaling Events



Normalization on number of viable cells using CellTiter-Fluor™





LCP: Live-cell protease



Signaling Pathway and Kinase Activity Analysis

Studying the NFκB Pathway



Modified from Hwang, B. *et al.* (2020) *Commun Biol.* 3:8



OBSERVATION

- IκBα phosphorylation at Ser32 (pS32)
- Immediately followed by rapid degradation



Signaling Pathway and Kinase Activity Analysis

Studying the NF κ B Pathway



Modified from Hwang, B. *et al.* (2020) *Commun Biol.* 3:8



OBSERVATION

- Decrease in I κ B α degradation
- Accumulation of phosphorylated I κ B α



Signaling Pathway and Kinase Activity Analysis

Studying the NF κ B Pathway



Modified from Hwang, B. *et al.* (2020) *Commun Biol.* 3:8

OBSERVATION

- Cycloheximide (CHX) blocks NF κ B-triggered *de novo* I κ B α biosynthesis

Lumit™ Immunoassay Cellular Systems


A Universal Immunoassay to Study Cellular Signaling



Validated with >20 phospho- and total proteins using 8 cell types, suggesting this universal immunoassay can be adapted for any pathway **with the appropriate antibodies**

- IκBα (phospho-Ser32 and total protein)
- STAT3 (phospho-Tyr705 and total protein)
- BTK (phospho-Tyr223)
- Estrogen receptor (total protein)
- β-Catenin (total protein)
- CREB (phospho-Ser133)
- P38 MAPK (phospho-Thr180/182)
- NFκB p65 (phospho-Ser536 and total protein)
- AKT (phospho-Ser473, phospho-Thr308, and total protein)
- Retinoblastoma tumor suppressor protein (phospho-Ser807/811 and phospho-Ser780)
- S6 ribosomal protein (phospho-Ser235/236, phospho-Ser240/244)
- MEK1/2 (phospho-Ser217/221, phospho-Ser298)

Application Notes






Available on Promega website with information on antibodies used



NanoLuc[®] Binary Technology (NanoBiT[®])


A Structural Complementation Reporter Designed for Biomolecular Interaction Studies





HiBiT Protein Tagging System

Principle & Features



- Nano-Glo[®] HiBiT Lytic Detection System
- Nano-Glo[®] HiBiT Extracellular Detection System
- Nano-Glo[®] HiBiT Blotting System
- Nano-Glo[®] Live Cell Substrates (up to 72 h)
+ co-expression of LgBiT (transient or stable)

Small Tag Size (11 aa, 1.3 kDa)

- Low risk artificially affect fusion partner

Easy Knock-in with CRISPR

- Work at native expression level
- Maintain transcriptional regulation
- Avoid gene dosage effects

Simple, Flexible & Rapid Detection

- Homogenous 1-step assay („add only“)
- No antibodies and no washing steps required
- Amenable to HTS and easy to automate



Sensitive & Quantitative

- Sub-attomolar levels can be detected
- High linear range of >7 logs



HiBiT Protein Tagging System

Principle & Features



Small Tag Size (11 aa, 1.3 kDa)

- Low risk artificially affect fusion partner

Easy Knock-in with CRISPR

- Work at native expression level
- Maintain transcriptional regulation
- Avoid gene dosage effects

Simple, Flexible & Rapid Detection

- Homogenous 1-step assay („add only“)
- No antibodies and no washing steps required
- Amenable to HTS and easy to automate


Sensitive & Quantitative

- Sub-attomolar levels can be detected
- High linear range of >7 logs



Strategies for Tagging with HiBiT

Ectopic Expression Using Constitutive Promoter-driven Plasmid



Your options


- 1 Promega's HiBiT entry vectors
 - N-terminal
 - C-terminal
 - N-terminal + IL-6 secretion sequence *
 - CMV, TK, PGK

* naturally occurring secretion signals shall be removed
- 2 Use existing vector and append HiBiT via PCR amplification
(e.g. internal placement of tag)



Generation of CRISPR/HiBiT Reporter Cells

Design of Target-specific CRISPR Components




- PAM as close as possible to integration site (knock-in↑)
- Ideally crRNA should span the insertion site
- Choose PAM to avoid cut in coding region
- Mutate PAM within the donor DNA

Validation of Genomic Editing in Cell Pools


Determination of Luminescence



Nano-Glo® HiBiT Lytic Detection System




Nano-Glo® Live-Cell Assay System



FACTS

- Signal ~ (knock-in %) x (expression level)
- Pick crRNA/donor combination with highest knock-in efficiency
- S/B > 10 is desirable for an assay
- CellTiter-Fluor™ can be used for normalization on viable cell number in plate-based assay

Nano-Glo® HiBiT Blotting System






CRISPR Cell Pools vs. Clones

Two Powerful Formats

A pool of CRISPR-modified cells may contain cells with a variety of genetic alterations:




- The only HiBiT signal comes from those cells with an appropriate HiBiT knock-in
- In a pool, much of the genetic variability (e.g. unwanted mutations) is averaged out
- Biological response of pools is usually very similar to isolated clones
- Pools are dimmer than clones but are often bright enough to use
A pool with 5% knock-in efficiency should be approx. 5% as bright as a clone



Generation of CRISPR/HiBiT Reporter Cells


Workflow for Edited Cell Clones





HiBiT Application Portfolio


One Bioluminescent Tag, Endless Possibilities





HiBiT Application Portfolio


One Bioluminescent Tag, Endless Possibilities





The HIF1 α Pathway




A Model System for Protein Stabilization





Stabilization of HIF1 α

The Relevance of Expression Level Protein Stabilization




- High expression levels mute the biological response
- endogenous expression yields highest assay window




Stabilization of HIF1 α

Maximize Information Content by Live-Cell Monitoring in Real-Time



Nano-Glo[®] Live Cell Substrate

- Nano-Glo[®] Live Cell Assay System (≤ 2 h)
- Nano-Glo[®] Vivazine[™] (2 - 24 h)
- Nano-Glo[®] Endurazine[™] (24 - 72 h)




phenanthroline


- HIF1 α
- BNIP3
- ANKRD37
- HILPDA
- KLF10



HiBiT Application Portfolio


One Bioluminescent Tag, Endless Possibilities






SARS-CoV-2 HiBiT-PsVLP Assay

Measure Blocking Activity for Small Molecule Inhibitors and Neutralizing Antibodies




- HiBiT-tagged VLPs pseudotyped with SARS-CoV-2 Spike protein are added to SARS-CoV-2 Target Cells




SARS-CoV-2 HiBiT-PsVLP Assay

Measure Blocking Activity for Small Molecule Inhibitors and Neutralizing Antibodies




- HiBiT-tagged VLPs pseudotyped with SARS-CoV-2 Spike protein are added to SARS-CoV-2 Target Cells
- Upon entry, GAG-HiBiT is released into target cells
- HiBiT binds to cellular LgBiT to generate a luminescent signal in the presence of luciferase substrate



SARS-CoV-2 HiBiT-PsVLP Assay

Measure Blocking Activity for Small Molecule Inhibitors and Neutralizing Antibodies





- HiBiT-tagged VLPs pseudotyped with SARS-CoV-2 Spike protein are added to SARS-CoV-2 Target Cells
- Upon entry, GAG-HiBiT is released into target cells
- HiBiT binds to cellular LgBiT to generate a luminescent signal in the presence of luciferase substrate
- Inhibitors that block entry/fusion processes prevent HiBiT release, i.e. no luminescent signal is produced



Monitor Infection in Real-Time

Determine Inhibitory Effects of Neutralizing Antibodies




- Entry of SARS-CoV-2 HiBiT-PsVLPs increased rapidly from 0 - 2 hours, then continued to increase slowly after 2 hours
- Entry of SARS-CoV-2 HiBiT-PsVLPs is inhibited in a dose-dependent manner by neutralizing antibody (nAb) and can be monitored over time




HiBiT Application Portfolio

One Bioluminescent Tag, Endless Possibilities





Study Receptor Internalization with HiBiT

GPCRs & RTKs



- Ectodomain of receptor tagged HiBiT
- Non-lytic detection with cell-impermeable LgBiT protein
- Measure both ligand potency and extent of internalization within minutes





Promega

THANK YOU!

QUESTIONS?

- For additional questions please contact:
erik.bonke@promega.com